Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma

This study is testing a new type of immune cell therapy — called CD19/CD20 CAR-T — for people with B-cell lymphoma (a blood cancer) that has come back or stopped responding to standard treatments. The therapy takes a patient's own immune cells, engineers them to attack cancer cells, and infuses them back. **You may be eligible if...** - You are aged 15–75 - You have B-cell lymphoma that has relapsed or is no longer responding to treatment - You have already tried at least two standard treatment regimens - Your tumor cells express a protein called CD20 - You are well enough to carry out daily activities (ECOG score 0–2) - Your heart, lungs, liver, and kidneys are working well enough **You may NOT be eligible if...** - You have already received CAR-T cell therapy - You have severe heart failure or heart disease - You have HIV, active hepatitis B or C, or syphilis - You have an uncontrolled active infection - You have an autoimmune disease requiring immunosuppressants - You are pregnant, breastfeeding, or planning pregnancy during the trial - You participated in another clinical study within the past 3 months Talk to your doctor to see if this trial is right for you.